Bronchoton - instructions for use, dose, side effects, contraindications

Active substanceGlaucin + Ephedrine + [Basil of common oil]Glaucin + Ephedrine + [Basil of common oil]

Similar drugsTo uncover

Broncholitin®

syrup inwards

Sopharma, AO Bulgaria

Bronchoton

syrup inwards

VetProm AD Bulgaria

Bronchocin®

syrup inwards

Balkanfarm - Troyan AD Bulgaria

Dosage form: & nbspsyrup

Composition:

125 g of syrup contain

active components: glaucine hydrobromide 0.125 g, ephedrine hydrochloride 0.100 g, basil of ordinary oil 0.125 g

auxiliary components: citric acid monohydrate 0.125 g, sucrose 43.750 g, methyl parahydroxybenzoate sodium 0.150 g, sodium propyl parahydroxybenzoate 0.025 g, polysorbate 80 1.250 g, ethanol 96% 1.500 g, water 125 grams

Description:

Syrup-like liquid of a yellowish brown color with a characteristic odor.

Pharmacotherapeutic group:Antitussive drug combined (antitussive drug of central action + sympathomimetic)

ATX: & nbsp

R.05.D.B Other antitussives

R.05.D.B.20 Combined preparations

Pharmacodynamics:

BRONCHOTON - a combined preparation of plant origin, has antitussive and bronchodilating effect.

Glaucin inhibits the cough center, without, however, leading to respiratory depression, constipation and drug dependence.

Ephedrine stimulates the respiratory center, expands the bronchi and (due to vasoconstrictive action) eliminates the edema of the bronchial mucosa.

Basil oil has a sedative (weak), antimicrobial and antispasmodic effect.

Pharmacokinetics:

Glaucine hydrobromide and ephedrine hydrochloride well absorbed in the digestive tract, creating and maintaining the necessary therapeutic levels in blood plasma. Excreted mainly in urine.

Indications:

In the complex therapy of diseases of the respiratory system, accompanied by a dry cough: acute and chronic bronchitis, tracheobronchitis, bronchial asthma, whooping cough.

Contraindications:

Hypersensitivity to the components of the drug.

Deficiency of sugarase / izamaltase, intolerance to fructose, glucose-galactose malabsorption (due to the content of sucrose in the preparation).

Ischemic heart disease, arterial hypertension, heart failure, arrhythmias, coronary atherosclerosis, pheochromocytoma, thyrotoxicosis, angle-closure glaucoma, diabetes mellitus, hyperthyroidism, prostatic hyperplasia, insomnia, pregnancy, period breastfeeding, children under 3 years old, future general anesthesia with cyclopropane or haloton.

Carefully:

Patients who are prone to develop drug dependence; patients with liver disease, alcoholism, epilepsy, brain diseases, craniocerebral trauma; children.

Dosing and Administration:

Adults - 1 tablespoon 3-4 times a day.

Children from 3 to 10 years - 1 teaspoon 3 times a day.

Children over 10 years - 2 teaspoons 3 times a day.

The duration of treatment is 5-7 days.

Side effects:

From the cardiovascular system: tachycardia, extrasystole, increased blood pressure.

From the nervous system: tremor, agitation, insomnia, dizziness.

From the digestive system: nausea, vomiting, loss of appetite and constipation.

From the endocrine system: increased libido, dysmenorrhea.

From the urinary system: difficulty urinating, urinary retention in patients with prostatic hyperplasia.

From the skin and mucous membranes: rash, increased sweating.

Allergic reactions: urticaria, bronchospasm, urticaria rash.

Others: impaired vision, tachyphylaxis.

Children - drowsiness.

Overdose:

Symptoms: nausea, vomiting, loss of appetite, circulatory circulation, tremor of the extremities, dizziness, sweating, difficulty urinating.

Treatment: wash the stomach, prescribe Activated carbon, further symptomatic treatment is indicated.

Interaction:

BRONCHOTON can be used simultaneously with antibiotics, antipyretic drugs and vitamins.

Included in the preparation ephedrine weakens the effects of narcotic and hypnotic drugs.

With simultaneous use with cardiac glycosides, some sympathomimetics, quinidine, tricyclic antidepressants, there is a risk of arrhythmias. Side effects can be observed and with simultaneous use with oxytocin or with preparations containing ergot alkaloids.

Combination BRONHOTON - monoamine oxidase (MAO) inhibitors - headache is possible, the risk of arrhythmia, hypertensive crisis, cerebral hemorrhage is increased. The drug BRONHOTON is available only 2 weeks after stopping the intake of MAO inhibitors.

BRONCHOTON reduces the hypotensive effect of sympatholytes due to the sympathomimetic effect of ephedrine.

With the joint application of the drug BRONHOTON with non-selective beta- adrenoblokatorami reduced broncholytic effect of the drug BRONHOTON and antihypertensive effect of beta-blockers.

With the simultaneous use of the drug with hypoglycemic agents for oral administration or insulin, a hypoglycemic effect may decrease.

Combination BRONCHOTON - dexamethasone reduces the therapeutic effect of dexamethasone.

BRONCHOTON is not recommended to be used simultaneously with expectorants (ambroxol, bromohexine, N-acetylcysteine) due to difficulty in expectoration of sputum.

When taking BRONCHOTON, it is not recommended to take drugs that alkalinize urine, such as sodium bicarbonate.

With the simultaneous use of the drug BRONHOTON with drugs that stimulate the central nervous system (CNS), or tonic beverages of plant origin (coffee, tea, coca-cola), it is possible to enhance the stimulating effect of the drug on the central nervous system.

Special instructions:

Due to the stimulating effect on the central nervous system and possible sleep disorders, it is not recommended to take the BRONCHOTON syrup after 16 hours.

If after 5-7 days after the beginning of treatment the symptoms of the disease persist or the condition worsens, it is necessary to consult a doctor.

BRONCHOTON contains up to 1.7% by volume of ethanol. A single dose for children from 3 to 10 years (5 ml) contains up to 0.069 g of alcohol, a daily dose of up to 0.20 g. A single dose for children over 10 years (10 ml) contains up to 0.138 g of alcohol, a daily dose of up to 0 , 40 g. A single dose for adults (15 ml) contains up to 0.207 g of alcohol, a daily dose of up to 0.60 g.

The syrup contains as auxiliary substances methyl- and propylparahydroxybenzoate, which, although rare, can cause hives, immediate-type hypersensitivity reactions with urticaria rash and bronchospasm.

The content of ephedrine in the composition of the product can give a positive result in the doping test in athletes.

Effect on the ability to drive transp. cf. and fur:The drug is not recommended for use in the performance of potentially hazardous activities requiring increased concentration and speed of psychomotor reactions.

Form release / dosage:

Syrup.

Packaging:

For 125 g in bottles of polyethylene terephthalate.

For 1 bottle with instructions for use in a cardboard bundle.

Storage conditions:

In a dry, the dark place at a temperature of 15 - 25 ° C Keep out of reach of children!

Shelf life:

4 years.

Do not use after expiry date!

Terms of leave from pharmacies:On prescription

Registration number:П N015265 / 01

Date of registration:15.08.2011

Expiration Date:Unlimited

The owner of the registration certificate:VetProm ADVetProm AD Bulgaria

Manufacturer: & nbsp

VETPROM, AD Bulgaria

Representation: & nbspVETPROM ADVETPROM ADBulgaria

Information update date: & nbsp07.03.2017

Illustrated instructions

Instructions

Bronchoton (Bronchoton)